drugset
drugset / Trial / NCT07590934

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934 ↗

Phase 1/2 Recruiting 152 enrolled AstraZeneca
RandomizedSequentialOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.

Timeline

Start
2026-06-03
Primary completion
2029-09-25
Completion
2029-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD9574 Small molecule — Oral
Comparator Docetaxel Small molecule — Intravenous
Subject FPI-2265 Small molecule — Intravenous
Background AZD2287 Diagnostic / imaging agent — Intravenous

Indications

metastatic prostate carcinoma